Close
Smartlab Europe
Inizio Ignite

Clinical Trials

Bharat Biotech underplays adverse event in Covaxin Phase 1 trial as start date for Phase 3 nears

Bharat Biotech, during its phase 1 trials, experienced an adverse event in a volunteer that it did not promptly admit to the public. As per a statement from the vaccine maker, the event was reported in a timely manner...

Astrazeneca Says AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were...

EUA Begins Rolling Review of Modernas mRNA Vaccine Candidate Against COVID-19

Moderna, Inc.,a biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that the EMA human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Company’s vaccine candidate...

Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients

Mallinckrodt plc, a global biopharmaceutical company, announced initiation of a retrospective chart review study, titled "Nitric Oxide Treatment In COVID-19 Evaluation (NOTICE)" to collect real-world data on the use of INOmax® (nitric oxide) gas, for inhalation therapy in patients...

Cancer Treatment Can Be Cloned For COVID-19

As per the recent international study by the scientists from Italy & Australia, Beta-blockers have it in them to be a potential treatment for COVID-19. The scientists are now calling for Clinical Trials to support the research findings. Dr. Nirmal...

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8,...

Pfizer Announces Positive Phase 3 Study Results for XELJANZ in Ankylosing Spondylitis

Pfizer Inc. announced positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS). Tofacitinib is not currently approved by the U.S. Food and Drug Administration (FDA) for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »